This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
by Zacks Equity Research
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.
Top Research Reports for NVIDIA, Netflix & Goldman Sachs
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA, Netflix, and Goldman Sachs, as well as a micro-cap stock, AMREP.
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
by Zacks Equity Research
KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Gilead Sciences (GILD) Fell More Than Broader Market
by Zacks Equity Research
Gilead Sciences (GILD) closed at $109.06 in the latest trading session, marking a -2.7% move from the prior day.
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention
by Zacks Equity Research
MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?
by Zacks Equity Research
Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill
by Zacks Equity Research
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Gilead Sciences (GILD) closed at $113.24, indicating a +1.96% shift from the previous trading day.
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
by Zacks Equity Research
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Gilead Sciences (GILD) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $110.67, marking a +2.83% move from the previous day.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
by Zacks Equity Research
Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.
Gilead Sciences (GILD) Stock Moves -1.18%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) concluded the recent trading session at $105.93, signifying a -1.18% move from its prior day's close.
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch
by Zacks Equity Research
GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.